Long-Term Safety and Efficacy of Certolizumab Pegol in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis: 5-Year Results from a 52-Week Randomized Controlled Trial and Open-Label Extension Study

被引：0
|
作者：
Keystone, Edward [1 ]
Landewe, Robert
van Vollenhoven, Ronald [2 ]
Combe, Bernard [3 ]
Strand, Vibeke [4 ]
Mease, Phillip [5 ,6 ]
Shaughnessy, Laura
VanLunen, Brenda
van der Heijde, Desiree [7 ]
机构：
[1] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
[2] Karolinska Inst, Stockholm, Sweden
[3] Hop Lapeyronie, F-34295 Montpellier, France
[4] Stanford Univ, Portola Valley, VA USA
[5] Swedish Med Ctr, Seattle, WA USA
[6] Univ Washington, Sch Med, Seattle, WA USA
[7] Leiden Univ, Med Ctr, Leiden, Netherlands
来源：
JOURNAL OF RHEUMATOLOGY | 2014年 / 41卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
24
引用
收藏
页码：1455 / 1456
页数：2
相关论文
共 50 条
  • [31] Combination therapy with certolizumab pegol plus methotrexate maintains long-term efficacy in the treatment of rheumatoid arthritis: A 2-year analysis
    Keystone, Edward C.
    Schiff, Michael H.
    Mease, Philip
    van Vollenhoven, Ronald F.
    Desai, Chintu
    Smolen, Josef
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S529 - S529
  • [32] Long-Term Safety and Efficacy of Tabalumab, an Anti-B-Cell Activating Factor Monoclonal Antibody, in Patients with Rheumatoid Arthritis: A 52-Week, Open-Label Extension Study.
    Greenwald, Maria W.
    Szczepanski, Leszek
    Kennedy, Alastair C.
    Lee, Chin H.
    Polasek, Emery
    Veenhuizen, Melissa
    Jones-Taha, Rebecca
    Berclaz, Pierre-Yves
    [J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S193 - S194
  • [33] Combination Therapy with Certolizumab Pegol Plus Methotrexate Maintains Long-term Efficacy in the Treatment of Rheumatoid Arthritis: A 2-year Analysis
    Haraoui, Paul
    Keystone, Edward
    Schiff, Michael
    Mease, Philip
    van Vollenhoven, Ronald F.
    Desai, Chintu
    Smolen, Josef
    [J]. JOURNAL OF RHEUMATOLOGY, 2009, 36 (11) : 2572 - 2572
  • [34] A MULTICENTER RANDOMIZED STUDY IN RHEUMATOID ARTHRITIS TO COMPARE IGURATIMOD, METHOTREXATE, OR COMBINATION: 52 WEEK EFFICACY AND SAFETY RESULTS OF THE SMILE TRIAL
    Du, F.
    Xu, J.
    Li, X.
    Li, Z.
    Li, X.
    Zuo, X.
    Bi, L.
    Zhao, D.
    Zhang, M.
    Wu, H.
    He, D.
    Wu, Z.
    Li, Z.
    Li, Y.
    Xu, J.
    Tao, Y.
    Zhao, J.
    Chen, J.
    Zhang, H.
    Li, J.
    Jiang, L.
    Xiao, Z.
    Chen, Z.
    Yin, G.
    Gong, L.
    Wang, G.
    Dong, L.
    Xiao, W.
    Bao, C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 574 - 575
  • [35] Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: A 12-week randomized controlled clinical trial with a 52-week open-label extension
    Reiff, A
    Lovell, DJ
    van Adelsberg, J
    Kiss, MHB
    Goodman, S
    Zavaler, MF
    Chen, PY
    Bolognese, JA
    Cavanaugh, PF
    Reicin, AS
    Giannini, EH
    [J]. JOURNAL OF RHEUMATOLOGY, 2006, 33 (05) : 985 - 995
  • [36] Long-term safety and efficacy of ropinirole in moderate-to-severe RLS: Results of two 52-week, open-label studies
    Dreykluft, T.
    Garcia-Borreguero, D.
    Lee, D.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 : 96 - 96
  • [37] Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52-week, open-label study
    Ishigooka, Jun
    Iwashita, Shuichi
    Tadori, Yoshihiro
    [J]. PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2018, 72 (06) : 445 - 453
  • [38] A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome
    Garcia-Borreguero, Diego
    Grunstein, Ronald
    Sridhar, Guruswamy
    Dreykluft, Tilman
    Montagna, Pasquale
    Dom, Rene
    Lainey, Eric
    Moorat, Anne
    Roberts, James
    [J]. SLEEP MEDICINE, 2007, 8 (7-8) : 742 - 752
  • [39] Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial
    Petersenn, S.
    Salgado, L. R.
    Schopohl, J.
    Portocarrero-Ortiz, L.
    Arnaldi, G.
    Lacroix, A.
    Scaroni, C.
    Ravichandran, S.
    Kandra, A.
    Biller, B. M. K.
    [J]. ENDOCRINE, 2017, 57 (01) : 156 - 165
  • [40] Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial
    S. Petersenn
    L. R. Salgado
    J. Schopohl
    L. Portocarrero-Ortiz
    G. Arnaldi
    A. Lacroix
    C. Scaroni
    S. Ravichandran
    A. Kandra
    B. M. K. Biller
    [J]. Endocrine, 2017, 57 : 156 - 165
12345